- Home
- HAE vs RXRX Comparison
HAE vs RXRX Comparison
Compare HAE & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAE
- RXRX
- Stock Information
- Founded
- HAE 1971
- RXRX 2013
- Country
- HAE United States
- RXRX United States
- Employees
- HAE N/A
- RXRX N/A
- Industry
- HAE Medical/Dental Instruments
- RXRX Biotechnology: Pharmaceutical Preparations
- Sector
- HAE Health Care
- RXRX Health Care
- Exchange
- HAE Nasdaq
- RXRX Nasdaq
- Market Cap
- HAE 2.5B
- RXRX 2.6B
- IPO Year
- HAE 1991
- RXRX 2021
- Fundamental
- Price
- HAE $71.92
- RXRX $4.71
- Analyst Decision
- HAE Strong Buy
- RXRX Buy
- Analyst Count
- HAE 9
- RXRX 4
- Target Price
- HAE $79.67
- RXRX $7.25
- AVG Volume (30 Days)
- HAE 949.3K
- RXRX 62.8M
- Earning Date
- HAE 11-06-2025
- RXRX 11-05-2025
- Dividend Yield
- HAE N/A
- RXRX N/A
- EPS Growth
- HAE 42.54
- RXRX N/A
- EPS
- HAE 3.44
- RXRX N/A
- Revenue
- HAE $1,327,850,000.00
- RXRX $43,689,000.00
- Revenue This Year
- HAE N/A
- RXRX $24.17
- Revenue Next Year
- HAE $6.35
- RXRX $20.96
- P/E Ratio
- HAE $20.88
- RXRX N/A
- Revenue Growth
- HAE N/A
- RXRX N/A
- 52 Week Low
- HAE $47.32
- RXRX $3.79
- 52 Week High
- HAE $94.99
- RXRX $12.36
- Technical
- Relative Strength Index (RSI)
- HAE 87.25
- RXRX 39.89
- Support Level
- HAE $49.96
- RXRX $4.18
- Resistance Level
- HAE $71.37
- RXRX $4.96
- Average True Range (ATR)
- HAE 2.27
- RXRX 0.38
- MACD
- HAE 2.60
- RXRX -0.17
- Stochastic Oscillator
- HAE 96.93
- RXRX 22.41
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.